BioStock: Cereno Scientific adds a clinical expert to its ODD track

Cereno Scientific develops innovative drugs for cardiovascular diseases, with a broadened focus on thrombosis and rare fibrosis-related cardiovascular diseases. Recently, the company’s lead candidate CS1 received Orphan Drug Designation from the FDA for the treatment of Pulmonary Arterial Hypertension. To further advance this opportunity, world leading PAH specialist Dr. Raymond L. Benza has been recruited as a Scientific Advisor.

Read the full article at biostock.se:

https://www.biostock.se/en/cereno-scientific-adds-a-clinical-expert-to-its-odd-track/ 

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se